More about Gordie Howe's therapy

Stem cells grown under low oxygen. These stem cells from Stemedica are licensed to CardioCell.

Dr. David Gorski, a prominent skeptic of therapies offered outside the scientifically controlled clinical trial system, has published an extensive and critical look at the stem cell therapy Gordie Howe received in early December to help him recover from a serious stroke.

I had email exchanges with Gorski while writing my article last week on the treatment, which uses stem cells provided by San Diego-based Stemedica. Gorski, whose previous blog post at Science-Based Medicine on Howe's treatment caught my attention, follows through with an analysis of the clinical trial setup used by Novastem, a Mexican stem cell company licensed by Stemedica to use its cells.

Dr. Murray Howe and his hockey great father, Gordie Howe, on a fishing trip in Saskatchewan in 2013. / Courtesy Murray Howe

"As sympathetic as I am to the Howe family, Im sorry. I reluctantly have to say that Murray Howe really should know better," Gorski wrote. "If Gordie Howe was treated as part of a clinical trial, then Novastem should have treated him for free! Thats because if it is running a clinical trial, it should treat everyone on the trial for free. Thats the way its done ethically."

I asked Novastem president Rafael Carrillo about the financial issue for my article. Carrillo said Novastem doesn't have deep pockets like a big pharmaceutical company, so it needs to charge for the treatment to pay its expenses. Without that money, it can't afford the trial. Patients wouldn't get the opportunity to get care that could help them, Carrillo said. Moreover, this arrangement is legal under Mexican law.

Gorksi views this as unethical, even if it's legal. He objects to the free treatment given to Gordie Howe, because it amounts to publicity for Novastem that will attract paying customers. And even if Howe is doing better, as appears to be the case, it's not possible to tell definitively whether stem cells helped.

The U.S. system has its own flaws, Gorski says, because patient expenses not related to the clinical trial are not paid for.

"Patients who dont have health insurance will often have a huge difficulty paying for their care not related to the clinical trial and thus will have difficulties accessing cutting-edge clinical trials because they cant pay for their own regular care," Gorski wrote. "Yay, USA!"

Stemedica is offering its own U.S. trial of the therapy, but people must have had the stroke at least six months ago. That's because people make the most improvement within six months after a stroke. So delaying treatment until after that point will make it easier to detect improvement caused by the stem cell treatment.

Continue reading here:
More about Gordie Howe's therapy

Malones donate $42.5 million to CSU for new stem-cell research facility

John and Leslie Malone pose with Maikel at Harmony Sporthorses, December 2, 2014.

The largest ever cash donation to Colorado State University stems from a novel treatment to get a dressage horse with a bum knee back into the show ring.

John and Leslie Malone's $42.5 million gift, announced Monday, will create the CSU Institute for Biologic Translational Therapies in the College of Veterinary Medicine and Biomedical Sciences, a 100,000-square-foot facility to develop stem-cell research into commercially viable treatments for animals and humans.

"This is the largest cash gift in the history of the university and it's absolutely staggering," said Brett Anderson, CSU's vice president for advancement. "It really allows us to be the best in the nation."

The Malone money will fund half of the $65 million cost to construct the facility. The school is looking for more donations to match the Malones' contribution. So far, an additional $10 million has been raised.

The Malones also provided $10 million to cover the Institute's operating expenses once the facility is built.

"The Malones have been so gracious. We asked them if they want to put their name on the building, but they said if it's helpful to you in order to get another major donor, we are happy to let you name it for someone else," Anderson said. "They are an incredible couple."

John Malone, who made his millions at the helm of Tele-Communications Inc. and now chairs the giant Liberty Media Corp., and his wife, Leslie, could not be reached for comment on Monday.

The Malones, who raise and train dressage and jumping horses on a ranch near Kiowa, last year donated $6 million to the school to establish the Leslie A. Malone Presidential Chair in Equine Sports Medicine.

They later brought Blixt, their dressage horse with a bad knee, to the vet school's Orthopaedic Research Center.

More:
Malones donate $42.5 million to CSU for new stem-cell research facility

Las Vegas Pain Management Clinic, Nevada Pain, Now Offering Over Ten Effective Treatments for Knee Arthritis with …

Las Vegas, Nevada (PRWEB) December 29, 2014

Top Las Vegas pain management clinic, Nevada Pain, is now providing over ten effective knee arthritis treatments. New treatments include regenerative medicine therapies such as PRP and stem cell therapy. Call (702) 323-0553 for more information and scheduling.

Knee arthritis affects tens of millions of Americans, often leading to significant disability. This may make it difficult to participate in recreational activities or play with one's kids or grandkids. While a total joint replacement typically has excellent outcomes, there are potential serious complications. Therefore, the procedure should be avoided or delayed until all other options have been attempted.

Nevada Pain offers the latest, cutting edge options for knee arthritis relief. This includes platelet rich plasma therapy, known as PRP therapy, along with stem cell therapy. The stem cell therapy is offered with either bone marrow derived stem cells or amniotic derived stem cells.

Additional treatments for knee arthritis include cortisone injections, which have been a gold standard for decades. They may provide months of consistent pain relief. Hyaluronic acid injections into the arthritic knee have been shown to offer six to twelve months of pain relief to most individuals.

Knee bracing is also offered along with TENS units, physical rehabilitation, pain medications and topical pain creams. Success rates are impressive for achieving pain relief and avoiding knee surgery.

Along with treating knee arthritis pain, Nevada Pain offers therapies for all types of back and neck pain, sciatica, scoliosis, neuropathy, RSD, spinal stenosis and much more. Treatment is offered by Board Certified, Award Winning providers.

Most insurance is accepted and there are multiple locations in the greater Las Vegas area. Call (702) 323-0553 for more information and scheduling.

More:
Las Vegas Pain Management Clinic, Nevada Pain, Now Offering Over Ten Effective Treatments for Knee Arthritis with ...

Ethics of Stem Cell Research (Stanford Encyclopedia of …

The potential therapeutic benefits of HESC research provide strong grounds in favor of the research. If looked at from a strictly consequentialist perspective, it's almost certainly the case that the potential health benefits from the research outweigh the loss of embryos involved and whatever suffering results from that loss for persons who want to protect embryos. However, most of those who oppose the research argue that the constraints against killing innocent persons to promote social utility apply to human embryos. Thus, as long as we accept non-consequentialist constraints on killing persons, those supporting HESC research must respond to the claim that those constraints apply to human embryos.

In its most basic form, the central argument supporting the claim that it is unethical to destroy human embryos goes as follows: It is morally impermissible to intentionally kill innocent human beings; the human embryo is an innocent human being; therefore it is morally impermissible to intentionally kill the human embryo. It is worth noting that this argument, if sound, would not suffice to show that all or even most HESC research is impermissible, since most investigators engaged in HESC research do not participate in the derivation of HESCs but instead use cell lines that researchers who performed the derivation have made available. To show that researchers who use but do not derive HESCs participate in an immoral activity, one would further need to establish their complicity in the destruction of embryos. We will consider this issue in section 2. But for the moment, let us address the argument that it is unethical to destroy human embryos.

A premise of the argument against killing embryos is that human embryos are human beings. The issue of when a human being begins to exist is, however, a contested one. The standard view of those who oppose HESC research is that a human being begins to exist with the emergence of the one-cell zygote at fertilization. At this stage, human embryos are said to be whole living member[s] of the species homo sapiens [which] possess the epigenetic primordia for self-directed growth into adulthood, with their determinateness and identity fully intact (George & Gomez-Lobo 2002, 258). This view is sometimes challenged on the grounds that monozygotic twinning is possible until around days 1415 of an embryo's development (Smith & Brogaard 2003). An individual who is an identical twin cannot be numerically identical to the one-cell zygote, since both twins bear the same relationship to the zygote, and numerical identity must satisfy transitivity. That is, if the zygote, A, divides into two genetically identical cell groups that give rise to identical twins B and C, B and C cannot be the same individual as A because they are not numerically identical with each other. This shows that not all persons can correctly assert that they began their life as a zygote. However, it does not follow that the zygote is not a human being, or that it has not individuated. This would follow only if one held that a condition of an entity's status as an individual human being is that it be impossible for it to cease to exist by dividing into two or more entities. But this seems implausible. Consider cases in which we imagine adult humans undergoing fission (for example, along the lines of Parfit's thought experiments, where each half of the brain is implanted into a different body) (Parfit 1984). The prospect of our going out of existence through fission does not pose a threat to our current status as distinct human persons. Likewise, one might argue, the fact that a zygote may divide does not create problems for the view that the zygote is a distinct human being.

There are, however, other grounds on which some have sought to reject that the early human embryo is a human being. According to one view, the cells that comprise the early embryo are a bundle of homogeneous cells that exist in the same membrane but do not form a human organism because the cells do not function in a coordinated way to regulate and preserve a single life (Smith & Brogaard 2003, McMahan 2002). While each of the cells is alive, they only become parts of a human organism when there is substantial cell differentiation and coordination, which occurs around day-16 after fertilization. Thus, on this account, disaggregating the cells of the 5-day embryo to derive HESCs does not entail the destruction of a human being.

This account is subject to dispute on empirical grounds. That there is some intercellular coordination in the zygote is revealed by the fact that the development of the early embryo requires that some cells become part of the trophoblast while others become part of the inner cell mass. Without some coordination between the cells, there would be nothing to prevent all cells from differentiating in the same direction (Damschen, Gomez-Lobo and Schonecker 2006). The question remains, though, whether this degree of cellular interaction is sufficient to render the early human embryo a human being. Just how much intercellular coordination must exist for a group of cells to constitute a human organism cannot be resolved by scientific facts about the embryo, but is instead an open metaphysical question (McMahan 2007a).

Suppose that the 5-day human embryo is a human being. On the standard argument against HESC research, membership in the species Homo sapiens confers on the embryo a right not to be killed. This view is grounded in the assumption that human beings have the same moral status (at least with respect to possessing this right) at all stages of their lives.

Some accept that the human embryo is a human being but argue that the human embryo does not have the moral status requisite for a right to life. There is reason to think that species membership is not the property that determines a being's moral status. We have all been presented with the relevant thought experiments, courtesy of Disney, Orwell, Kafka, and countless science fiction works. The results seem clear: we regard mice, pigs, insects, aliens, and so on, as having the moral status of persons in those possible worlds in which they exhibit the psychological and cognitive traits that we normally associate with mature human beings. This suggests that it is some higher-order mental capacity (or capacities) that grounds the right to life. While there is no consensus about the capacities that are necessary for the right to life, some of the capacities that have been proposed include reasoning, self-awareness, and agency (Kuhse & Singer 1992, Tooley 1983, Warren 1973).

The main difficulty for those who appeal to such mental capacities as the touchstone for the right to life is that early human infants lack these capacities, and do so to a greater degree than many of the nonhuman animals that most deem it acceptable to kill (Marquis 2002). This presents a challenge for those who hold that the non-consequentialist constraints on killing human children and adults apply to early human infants. Some reject that these constraints apply to infants, and allow that there may be circumstances where it is permissible to sacrifice infants for the greater good (McMahan 2007b). Others argue that, while infants do not have the intrinsic properties that ground a right to life, we should nonetheless treat them as if they have a right to life in order to promote love and concern towards them, as these attitudes have good consequences for the persons they will become (Benn 1973, Strong 1997).

Some claim that we can reconcile the ascription of a right to life to all humans with the view that higher order mental capacities ground the right to life by distinguishing between two senses of mental capacities: immediately exercisable capacities and basic natural capacities. (George and Gomez-Lobo 2002, 260). According to this view, an individual's immediately exercisable capacity for higher mental functions is the actualization of natural capacities for higher mental functions that exist at the embryonic stage of life. Human embryos have a rational nature, but that nature is not fully realized until individuals are able to exercise their capacity to reason. The difference between these types of capacity is said to be a difference between degrees of development along a continuum. There is merely a quantitative difference between the mental capacities of embryos, fetuses, infants, children, and adults (as well as among infants, children, and adults). And this difference, so the argument runs, cannot justify treating some of these individuals with moral respect while denying it to others.

Given that a human embryo cannot reason at all, the claim that it has a rational nature has struck some as tantamount to asserting that it has the potential to become an individual that can engage in reasoning (Sagan & Singer 2007). But an entity's having this potential does not logically entail that it has the same status as beings that have realized some or all of their potential (Feinberg 1986). Moreover, with the advent of cloning technologies, the range of entities that we can now identify as potential persons arguably creates problems for those who place great moral weight on the embryo's potential. A single somatic cell or HESC can in principle (though not yet in practice) develop into a mature human being under the right conditionsthat is, where the cell's nucleus is transferred into an enucleated egg, the new egg is electrically stimulated to create an embryo, and the embryo is transferred to a woman's uterus and brought to term. If the basis for protecting embryos is that they have the potential to become reasoning beings, then, some argue, we have reason to ascribe a high moral status to the trillions of cells that share this potential and to assist as many of these cells as we reasonably can to realize their potential (Sagan & Singer 2007, Savulescu 1999). Because this is a stance that we can expect nearly everyone to reject, it's not clear that opponents of HESC research can effectively ground their position in the human embryo's potential.

Link:
Ethics of Stem Cell Research (Stanford Encyclopedia of ...

Human Embryonic Stem Cells – Research – Stem Cell Biology …

One of the institute's research goals is to explore the potential of using embryonic stem cells to better understand and treat disease. Unlike adult stem cells, embryonic , or pluripotent, stem cells are not restricted to any particular tissue or organ and are capable of producing all cell types. By studying how these cells develop into mature cells, such as those that make up our bone, blood and skin, researchers can learn how those cells function and what goes wrong when they are diseased.

With this understanding, researchers aim to develop new medical strategies capable of extending the capacity for growth and healing present in embryos into later stages of life. Such strategies would regenerate or replenish tissues or specialized cells damaged by Alzheimer's, cancer and other chronic, debilitating and often fatal diseases.

At Stanford, pluripotent stem cells have already been used experimentally to treat mice with diabetes. Researchers found a set of growth factors that induced pluripotent stem cells to develop into insulin-producing cells normally found in the pancreas. When they implanted these cells into diabetic mice that have lost the ability to produce insulin, the implanted cells produced insulin in a biologically normal way and treated the diabetes. This work is still in the early stages of being tested in animals, but could one day lead to new ways of treating diabetes in people.

Pluripotent stem cells, like adult brain stem cells, might also replace nerves damaged in spinal cord injuries or cells lost in neurodegenerative diseases. For any of these treatments to work, researchers have to first learn how to grow the stem cells in a lab so they take on the characteristics of the cells they are meant to replace. At this time it isn't clear whether pluripotent or adult stem cells will be best in this type of therapy.

Follow this link:
Human Embryonic Stem Cells - Research - Stem Cell Biology ...

Center for Stem Cell Biology | Memorial Sloan Kettering …

The Center for Stem Cell Biology (CSCB) was established in 2010 to serve as a hub for existing stem cell efforts at Memorial Sloan Kettering Cancer Center. The center also supports targeted recruitment of stem cell faculty and provides resources for stem cell research such as core facilities and trainings programs.

Memorial Sloan Kettering has been a leader in various aspects of stem cell research for many years. It has been at the forefront of realizing the potential of hematopoietic stem cells in the treatment of hematopoietic malignancies, the use of umbilical cord blood as a source of stem cells suitable for transplantation, and the isolation of human mesenchymal stem cells. In recent years research has expanded to new areas such as neural stem cells, embryonic stem cells, and induced pluripotent stem cells. The CSCB will link these existing stem cell research efforts and build the resources critical for new developments in the future.

Career Opportunities Faculty positions are currently available in the Stem Cell Biology Program More

To achieve these goals the CSCB will bring together scientists across various programs with a broad range of expertise in the following areas: cancer pathogenesis, cell biology, chemical biology, computational biology, developmental biology, and pharmacology. These partnerships will facilitate research projects that transcend traditional departmental boundaries to explore the full potential of stem cells, ranging from basic developmental studies to the use of human stem cells in drug discovery. Another core mission of the CSCB is the training of investigators in stem cell technologies such as induced pluripotency, directed differentiation, genetic modification, and prospective purification of stem cells. Finally, the CSCB links stem cell efforts at Memorial Sloan Kettering with the Tri-Institutional Stem Cell Initiative, a collaborative program of Memorial Sloan Kettering, The Rockefeller University, and Weill Cornell Medical College, as well as with other national and international stem cell organizations.

Read this article:
Center for Stem Cell Biology | Memorial Sloan Kettering ...

Record competition for stem cell grants means tough choices for state officials

The competition for Maryland's stem cell research grants will be stiffer than ever as applications flood in next month, forcing officials to be more selective even as scientists worry that the state's fiscal problems and a new administration in Annapolis may mean smaller budgets in the future.

The Maryland Stem Cell Research Commission received a record 240 letters declaring intent to apply for $10.4 million in grants, officials said this month. While the majority came from researchers, more than a dozen came from startups and other companies and half a dozen for work testing therapies on humans proof that the 8-year-old program is boosting the state's biotechnology industry, officials said.

But that also means the state likely will reject more applications for the grants than in previous years. And with no funding promises from Gov.-elect Larry Hogan and state budget cuts looming, researchers worry there will be less to go around in 2016 and beyond.

The uncertainty comes just as advancements in stem cell science are making more research possible, threatening progress in Maryland even as other states surge forward, researchers said.

"In California, they have $3 billion. Here, we have $10 million a year. It is very hard," said Ricardo Feldman, an associate professor of microbiology and immunology at the University of Maryland School of Medicine. "Not all of us who have exciting results are going to get it, and some of us who do not get funding will not be able to continue what we started, and that will be very sad."

At an annual symposium on state-funded stem cell research this month, state stem cell commission officials said they received letters of intent from a record 16 companies as well as seven proposals for clinical work and 144 proposals for "translational" work research that aims to turn basic science into viable therapies. Applications are due Jan. 15.

Historically, the awards have gone more for university research and projects that are still at least a few steps away from being used in hospitals, but the surge in commercial and clinical work is a product of the state's long-term commitment to the grants, said Dan Gincel, the stem cell research fund's executive director.

The grants help research projects advance to a stage where they can attract backers like drug companies or other for-profit investors, who are more discriminating in the projects they support since many end up going nowhere.

"A long-term commitment is extra important for something so high-risk," Gincel said. "You gain trust that this is going somewhere."

There aren't many investors for researchers to turn to early on, said Jennifer Elisseeff, a professor of biomedical engineering at the Johns Hopkins University who has been part of teams receiving $920,000 in state grants over the past two years. She and colleagues are exploring how to stimulate stem cells to regrow tissues, a project she called "kind of basic science-y but also very applied."

Read more:
Record competition for stem cell grants means tough choices for state officials

Freezing newborns own stem cells for possible future use

CORDLIFE is now the largest network of private cord blood banks in Asia Pacific with state-of-the-art cord-blood and tissue processing and cryopreservation facilities in the country.

Once considered a medical waste, the blood left in the umbilical cordthe part of the placenta that delivers nutrients to a fetusafter a baby is delivery is now known to be a rich source of blood-forming stem cells.

These cells have been found to be potentially useful in treating diseases that require stem cell transplants (also called bone marrow transplants) such as certain kinds of leukemia or lymphoma, aplastic anemia (a blood disorder in which the bodys bone marrow doesnt make enough new blood cells), severe sickle cell disease and severe combined immunodeficiency.

Unlike with bone marrow, which is obtained through a painful medical procedure, there is only one chance to collect this seemingly precious stuff: immediately after the babys birth.

This is why a number of expectant parents in the country are being offered a chance to save stem cells from their babys umbilical cord blood via what is known as cord-blood banking.

Safeguard

Cordlife Philippines medical director Arvin Faundo said: Its a type of safeguard because the genetically unique stem cells have current and potential uses in medical treatment. No parent wishes his/her child to experience the heartbreaking effects of any illness. What we at Cordlife offer them is the chance to prepare for potential eventualitiesto secure the future well-being and happiness of their family.

Cordlife Philippines is a subsidiary of Cordlife Group Ltd., a company listed on the Singapore Exchange. Launched in February 2010 as the Philippines first and only cord-blood processing and cryopreservation facility, its facility was ISO-certified and built in accordance to global gold standards such as the American Association of Blood Banks.

The 365-day facility, located within UP-Ayala Land TechnoHub in Quezon City, is equipped with the worlds most advanced fully automated cord-blood processing system, the Swiss-made Sepax.

CordLife uses the US FDA-approved cryogenic storage pouch.

Originally posted here:
Freezing newborns own stem cells for possible future use

Aggie grad happy to put off retiring to advance stem cell science

David Eller could have retired a long time ago.

At the age of 76, he could spend his days on permanent vacation fly-fishing in Idaho, golfing in San Antonio or skiing on the Italian-Austrian border like he has done to get away from work for many years.

He isn't working because he is desperate for money and accolades. He's had those for many years.

During the '80s, Eller oversaw revolutionary cattle cloning practices as CEO of Granada BioSciences, a company he founded. He served as chairman of the Texas A&M System Board of Regents from 1983 to 1989. The Oceanography & Meteorology Building on A&M's campus was named in his honor in 1988.In 2000, he was namedexecutive vice president and president of DuPont's European operations.He is president of Eller Holding Company, a privately-held family investment company.

Instead of settling down after a life of amassing great wealth and personal achievement, he co-founded Houston-based Celltex Therapeutics Corporation in 2011 and put himself at the forefront of the contentious issue of autologous stem cell therapy in the name of fighting for ill people to harness the healing properties of their own bodies.

These days it is Celltex that drives Eller's passion, enabling him to combine his humanitarian and entrepreneurial impulses and perhaps one day leave a lasting mark on health care. It is the culmination of the journey he began on the A&M campus in the late 1950s.

"When I started this company I really didn't need another job," Eller said. "I certainly didn't need one with so many rules and regulations we had to adhere to that gives us a lot of headaches. All in all, the biggest reward out of it is seeing people improve their quality of life."

Since 2011, the company has helped treat approximately 600 patients between the ages of 6 and 96 by injecting stem cells taken from their own bodies into a troubled area with no complications, according to Eller. He believes Celltex's reach could expand tenfold if the entire operation could be conducted out of the United States, where the practice was banned in 2012, but that could take years of fighting a two-front war.

The daily war is educating as many doctors and potential patients as possible on the benefits of being treated with a one's own stem cells. The second, long-term war is maneuvering through the FDA's web of red tape that currently bans the practice from being performed on U.S. soil.

Eller spent four years in the Texas A&M Corps of Cadets until his 1959 graduation, which he says plays a major role in his character.

Continue reading here:
Aggie grad happy to put off retiring to advance stem cell science